Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist.
Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn about financial terms, types of investments, trading strategies and more. Nabriva Therapeutics plc (NASDAQ:NBRV) traded at $0.54 at last check on Friday, Oct 02, making an upward move of 1.13% on its previous day’s price. Nabriva Therapeutics' stock is owned by a number of retail and institutional investors. View the latest Nabriva Therapeutics PLC (NBRV) stock price, news, historical charts, analyst ratings and financial information from WSJ. Find real-time NBRV - Nabriva Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business. Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, Gary Sender, Steven P Gelone and Theodore R Schroeder. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Learn everything you need to know about successful options trading with this three-part video course. Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media. View which stocks have been most impacted by COVID-19. You may vote once every thirty days.
Volatility and Risk. See what's happening in the market right now with MarketBeat's real-time news feed. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. (Add your “outperform” vote. View institutional ownership trends for Nabriva Therapeutics.
United States. One share of NBRV stock can currently be purchased for approximately $0.48. Specifically, they have bought $0.00 in company stock and sold $7,192.00 in company stock. Sie können Ihre Einstellungen jederzeit ändern. Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, Gary Sender, Steven P Gelone and Theodore R Schroeder. With a year-over-year growth in debt of -69.24%, Nabriva Therapeutics plc's debt growth rate surpasses merely 3.41% of about US stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN.
Nabriva Therapeutics has only been the subject of 1 research reports in the past 90 days. Nabriva Therapeutics PLC - (NASDAQ:NBRV) released its quarterly earnings data on Thursday, August, 6th. Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. aus oder wählen Sie 'Einstellungen verwalten', um weitere Informationen zu erhalten und eine Auswahl zu treffen. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]. Find the latest Nabriva Therapeutics plc (NBRV) stock quote, history, news and other vital information to help you with your stock trading and investing. NBRV 0.50 0.01 (2.84%). Rooms Rankings Earnings Calendar Shop. Fundamental company data and analyst estimates provided by FactSet. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements.
The stock has a … Cancel. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
You can change your choices at any time by visiting Your Privacy Controls. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View our full suite of financial calendars and market data tables, all for free. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. Dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen. View our earnings forecast for Nabriva Therapeutics. Top institutional shareholders include WINTON GROUP Ltd (0.03%), Exane Derivatives (0.01%) and Exane Derivatives (0.01%). Nabriva Therapeutics has received 378 “outperform” votes. Looking for new stock ideas? The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. Find real-time NBRV - Nabriva Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business.
All Rights Reserved. Stock analysis for Nabriva Therapeutics PLC (NBRV:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Yahoo ist Teil von Verizon Media. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Top institutional investors include WINTON GROUP Ltd (0.03%), Exane Derivatives (0.01%) and Exane Derivatives (0.01%). Change value during other periods is calculated as the difference between the last trade and the most recent settle. The average Nabriva Therapeutics stock price prediction forecasts a potential downside of 72.29% from the current NBRV share price of $0.58.
NBRV is not currently paying a regular dividend. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. All rights reserved. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released.
With a price/sales ratio of 83.47, Nabriva Therapeutics plc has a higher such ratio than 96.98% of stocks in our set.